Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 2

Status

Completed 3Active not recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Renal Cell 5Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1

Interventions

Carboplatin 36Cisplatin 32pembrolizumab 30Paclitaxel 29Pemetrexed 22Gemcitabine 21Nivolumab 19Dexamethasone 17Rituximab 16Fluorouracil 13Docetaxel 13durvalumab 12Ipilimumab 12Capecitabine 12Cyclophosphamide 11atezolizumab 10130-nm albumin-bound paclitaxel 10olaparib 9Trastuzumab 9Lenalidomide 9Doxorubicin 9Cytarabine 9Bevacizumab 9daratumumab 8Oxaliplatin 8Bortezomib 8Vinorelbine 7Prednisone 7Leucovorin 7venetoclax 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Sunitinib × Clear all
NCT02231749 2026-05-27

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Bristol-Myers Squibb

Phase 3 Completed
1,096 enrolled 17 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02811861 2026-02-23

CLEAR

Eisai Inc.

Phase 3 Active not recruiting
1,069 enrolled 12 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02853331 2026-02-02

KEYNOTE-426

Merck Sharp & Dohme LLC

Phase 3 Completed
861 enrolled 24 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Pfizer

Phase 3 Completed
886 enrolled 37 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03141177 2025-06-06

CheckMate 9ER

Bristol-Myers Squibb

Phase 3 Active not recruiting
701 enrolled 17 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡